Inventaire - your friends and communities are your best library

Anticoagulation by factor Xa inhibitors

Published in: Journal of Thrombosis and Haemostasis

Date of publication: May 21, 2010

Main subject: anticoagulation

Bibliographic databases:

Cites articles 31

Date

Title

Authors

August 1, 1983

Thrombin activity of fibrin thrombi and soluble plasmic derivatives
January 1, 1986

Purification of six human vitamin K-dependent proteins in a single chromatographic step using immunoaffinity columns
April 1, 1989

The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model
August 1990

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
June 25, 1992

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
September 1, 1995

The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity
October 1, 1996

Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa
September 1, 1997

Low-Molecular-Weight Heparins
March 1, 1997

Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition
January 1, 2000

The origin of the dispute over the discovery of heparin
October 1, 2000

Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy
November 1, 2001

Oral anticoagulation thresholds,Oral Anticoagulation Thresholds
April 1, 2001

Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex
August 1, 2001

Platelets and phospholipids in tissue factor-initiated thrombin generation
July 1, 2003

Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites

,
June 1, 2003

Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex
September 1, 2004

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
September 1, 2004

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
June 1, 2004

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial
October 7, 2005

The tissue factor requirement in blood coagulation
July 1, 2005

The plasma hemostatic proteome: thrombin generation in healthy individuals
March 2005

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor
January 1, 2005

The challenge of regulating anticoagulant drugs: focus on warfarin
September 2006

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin
January 1, 2006

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
June 1, 2006

Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium
February 1, 2007

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
February 11, 2008

The nature of the stable blood clot procoagulant activities
July 11, 2008

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
September 1, 2008

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

,
April 1, 2010

New anticoagulants

,

Article -

Welcome to inventaire

The library of your friends and communities

Learn more